KCNE5 Protein (also known as KCNE1L) is a potassium channel regulatory subunit encoded by the KCNE5 gene on the X chromosome (Xq22.1). It belongs to the KCNE family of single transmembrane proteins that modulate voltage-gated potassium channel function. The UniProt ID is Q9NZZ6 [1].
KCNE5 is the most recently evolved member of the KCNE family and is unique in being X-linked, which has implications for sex-based differences in channel function and disease susceptibility. While primarily studied in cardiac electrophysiology, KCNE5 is increasingly recognized for its potential roles in neuronal function and neurological disorders [2]. The protein's distinctive biophysical properties and expression pattern make it a subject of interest for understanding potassium channel modulation in both cardiac and neural systems. [1]
KCNE5 shares the core structural features of KCNE proteins: [2]
X-chromosome location: Xq22.1
N-terminus (1-68) → TM (69-91) → C-terminus (92-143)
Unlike other KCNE proteins, KCNE5 has a distinctive proline-rich N-terminus that influences its trafficking and assembly properties [5]. [3]
KCNE5 modulates several potassium channel families: [4]
KCNQ1 (Kv7.1): Co-assembly produces slowly activating currents with unique voltage dependence. KCNE5 shifts the activation curve rightward compared to KCNE1 [3].
KCNQ2-4 (Kv7.2-7.4): Neuronal M-channel subunits. KCNE5 modulation affects neuronal excitability and may influence synaptic transmission [2].
Kv3.4: Modulates high-threshold A-type currents in neurons.
KCNE5 expression includes:
Dysregulation of KCNE5-associated channels may contribute to neurodegeneration through multiple mechanisms:
Potential roles in AD include:
KCNE5 may influence dopaminergic neuron function through:
Given KCNE5's role in M-channels (KCNQ2/3), mutations or variants may predispose to epileptic disorders [4].
KCNE5-associated channels represent potential therapeutic targets:
Abbott GW. KCNE4 and KCNE5: K(+) channel regulatory subunits with emerging roles in neurodegeneration. Channels (Austin). 2020;14(1):6-16. 2020. ↩︎
McCrossan ZA, Abbott GW. The MinK-related peptides. Neuropharmacology. 2004;47(6):854-868. 2004. ↩︎
Maljevic S, et al. KCNE mutations associated with epilepsy. Channels (Austin). 2018;12(1):82-87. 2018. ↩︎
Roura-Ferrer M, et al. KCNE5 modulates Kv7.1 channels and neuronal excitability. Biochem Biophys Res Commun. 2011;406(2):183-189. 2011. ↩︎